Your browser doesn't support javascript.
loading
Association of CSF proteins with tau and amyloid ß levels in asymptomatic 70-year-olds.
Remnestål, Julia; Bergström, Sofia; Olofsson, Jennie; Sjöstedt, Evelina; Uhlén, Mathias; Blennow, Kaj; Zetterberg, Henrik; Zettergren, Anna; Kern, Silke; Skoog, Ingmar; Nilsson, Peter; Månberg, Anna.
Afiliación
  • Remnestål J; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Tomtebodvägen 23A, Solna, Stockholm, Sweden.
  • Bergström S; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Tomtebodvägen 23A, Solna, Stockholm, Sweden.
  • Olofsson J; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Tomtebodvägen 23A, Solna, Stockholm, Sweden.
  • Sjöstedt E; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Tomtebodvägen 23A, Solna, Stockholm, Sweden.
  • Uhlén M; Department of Neuroscience, Karolinska Institutet, Solna, Sweden.
  • Blennow K; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Tomtebodvägen 23A, Solna, Stockholm, Sweden.
  • Zetterberg H; Department of Neuroscience, Karolinska Institutet, Solna, Sweden.
  • Zettergren A; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Kern S; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Skoog I; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Nilsson P; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Månberg A; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Alzheimers Res Ther ; 13(1): 54, 2021 03 02.
Article en En | MEDLINE | ID: mdl-33653397
ABSTRACT

BACKGROUND:

Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer's disease (AD) is important for the understanding of disease pathophysiology and also crucial to be able to identify and validate disease biomarkers. While several biological changes that occur early in the disease development have already been recognized, the need for further characterization of the pathophysiological mechanisms behind AD still remains.

METHODS:

In this study, we investigated cerebrospinal fluid (CSF) levels of 104 proteins in 307 asymptomatic 70-year-olds from the H70 Gothenburg Birth Cohort Studies using a multiplexed antibody- and bead-based technology.

RESULTS:

The protein levels were first correlated with the core AD CSF biomarker concentrations of total tau, phospho-tau and amyloid beta (Aß42) in all individuals. Sixty-three proteins showed significant correlations to either total tau, phospho-tau or Aß42. Thereafter, individuals were divided based on CSF Aß42/Aß40 ratio and Clinical Dementia Rating (CDR) score to determine if early changes in pathology and cognition had an effect on the correlations. We compared the associations of the analysed proteins with CSF markers between groups and found 33 proteins displaying significantly different associations for amyloid-positive individuals and amyloid-negative individuals, as defined by the CSF Aß42/Aß40 ratio. No differences in the associations could be seen for individuals divided by CDR score.

CONCLUSIONS:

We identified a series of transmembrane proteins, proteins associated with or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport to be associated with CSF biomarkers of amyloid and tau pathology in AD. Further studies are needed to explore these proteins' role in AD pathophysiology.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Alzheimers Res Ther Año: 2021 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Alzheimers Res Ther Año: 2021 Tipo del documento: Article País de afiliación: Suecia